scimus quid non scimus
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mullen FIVE ...LA Auto Show
Mullen Five - World Debut and First Look
Mullen FIVE...
"The most BLATANT market manipulation I've ever seen"...
Mullen Ramps Up EV Assembly Line
https://www.assemblymag.com/articles/96902-mullen-ramps-up-ev-assembly-line
Good Fortune Cometh...Except to the S2PIDScamJunk Messengers.
$$$$$^ Will Watch N Wait for ReEntry again.eom
Winnaar123 MULN HQ in Brea,Ca is Pretty Close to my Main Residence in Anaheim Hills,Ca.
Looking fwd for the Next LA Auto Show...by then,MAI already have Production Xover EV's in the Streets Of Southern Cali4nia.
I will Have 2 Free Five Xovers when the PPS gets over $5/sh
https://finviz.com/quote.ashx?t=MULN
https://finance.yahoo.com/news/mullen-automotive-issues-letter-shareholders-100000768.html
If You are Not Crankin for daily ATM$ here...The You are being Scam by a ShortFool.
Watch The STCM MTM 3Min Chart...Buy when the SineWave Head is @ the BuyZone...below the -40 Grid. ^$
This is a Great daily ATM$ Maker for Now.eom
DAILY SUPER ATM$$$ ^ eom
$$$$$^SM NKLA is Truly a Fake One.MULN CEO Prolly BadBoy Too but Smarter... Big Money Put Huge Money @ the LA Auto Show.
Unbelievers Quit and Gave Up during the early days of Tesla.
EM has a Martian Brain...that He may Support Mullen Batt Tech.Yaa Never know.
The MULN ShortFools are Actually building up their Hodlings here...
The $GME Day will come...
The Previous PO TUS is a Known Fraudster,Liar and Scammer and yet his association with still Non-Functional SM is Trading @ almost a $100/sh
Tickle The ATM$ and Baghodl for Banking!!!
Someone,or an Entity will Take Care of the Buss.The Foundation was Laid down and Too Much $ already invested and Involved by some Wealthy Men.
I hear a Great Proposition as the HQ is just in my Neigborhood.The Old GraveYard was Toooo Old as a News or DD by a TombStone Digger.lol
Like Buying PanCakes today Compared to those who bought over $10/sh Last year.
Happy 8747^
188M TV and Down 6 Tickles eot.KraZZZyyy.eom
Do it Now @ under 0.95 eom
There Yaaa Go SM Your 0.92 TradeCast earlier.KraZZZyyy atm$.eom
One Dollar Loaded!!!^$.MManipulators will Run it Today.jmhtto.eom
LoveltlnBishop...Thanks for the Tip...
Will Pass-by the HQ In Brea,Ca.I may go to the Brea Mall anyway.
Trade the MManipulation for atm$ and Baghodl the Cheappies for Banking.eom
99/66 Cents...for Baghodling.eom
WATT Partners Bluetoot etc...
https://energous.com/company/partners/
https://energous.com/
Recently
Energous Granted FCC Approval for Unlimited Distance Over-the-Air Wireless Charging
https://finance.yahoo.com/news/energous-granted-fcc-approval-unlimited-103000158.html
$WATT Energous Enables Wireless Power Transfer Solutions at any Distance for U.S. and Europe
https://www.eetimes.eu/energous-enables-wireless-power-transfer-solutions-at-any-distance-for-u-s-and-europe/
https://energous.com/
https://finviz.com/quote.ashx?t=WATT
Over $22/sh 3 years ago
Energous is redefining wireless power charging with its WattUp® technology.
We have a full spectrum of RF-based wireless power solutions – near field, desktop and charging-at-a-distance
The only second-generation wireless charging company shipping with partner product on the market
First FCC Part 18 Certification for Power-at-a-Distance
Approved to ship in 112 countries including the E.U., Japan and North America
Over 200 patents
World-class engineering expertise in RF, analog/mixed-signal IC, antennas, software, hardware and system design.
Energous To Demonstrate WattUp Wireless Charging Over-The-Air Technology and Partner Products at CES 2022
https://www.businesswire.com/news/home/20210913005135/en/Energous-To-Demonstrate-WattUp-Wireless-Charging-Over-The-Air-Technology-and-Partner-
WATT Is Currently Trading Like my AMD five years ago @ Low $2.
PB I will Change The Ticker today...but my Bid
for 3M shares X 0.02 need to be Filled
first.
On Nov 01 a Retail Closed her/his Account
@ Market Sells.
This Board need some Giggles...
MRNA may Buy Out Medolife Rx as the Company need Something New in their
Lab.
Their Vaccine Losing its Efficacy Today. Lol
OK have a great weekend.
My Fidelity Active Trader Pro (Level II) Not SHOWING Bid and Ask.
Me thinks those 9500 trades are Algos...
Never seen Them before on my E*Trade Pro Level II Account,These Nasty 9500
Trades started sometimes in May If I Recall it Right.Will Check my ScreenShots...when I get the Chance.
Sold 12K shars of N VDA earlier after 3 Years.Holding some more.
I have an IRA Account for Sure.
^$
Escozine® for China’s Latest Delta Outbreak its Most Widespread Since Wuhan
https://www.msn.com/en-us/news/world/china-s-latest-delta-outbreak-its-most-widespread-since-wuhan/ar-AAQgiAh?ocid=msedgdhp&pc=W069
CHEK Buy:Reasons...
https://finviz.com/quote.ashx?t=CHEK&ty=c&ta=1&p=d
No More Pathtetic Invasive Butthole Insertion
https://check-cap.com/
Reasons I’m Accumulating/Baghodling...This will be my Next OCGN.
- They strengthened balance sheet to $56M
- $3 book value.
- Just received patent approval.
- Avoided delisting notice by finishing over $1 yesterday.
- Increased manufacturing with their GE partnership.
- Have plenty of money to make it through their trials.
- ARK Invest is in here.
- Given a buy rating by H.C Wainwright.
- Great technology that has been proven to be better than competitors.
^$
Medolife Rx 2day Quarter Bound Listed.eom
Medolife Rx OTCQB Uplisting News just Posted on Fidelity and ETrade Pro
Medolife Rx Announces Uplisting to OTCQB Venture Market
By GlobeNewswire
— 8:00 AM ET 11/03/2021
BURBANK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (QNTA.NaE) , announced today its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market (the “OTCQB”). Quanta’s stock symbol will remain QNTA on the OTCQB while the Company awaits a name and symbol change to be approved by FINRA.
“We have been working diligently to complete the proper filings and audits necessary for this uplisting, and we’re happy to announce that we have been approved to trade on the OTCQB Market,” said Medolife CEO Dr. Arthur Mikaelian. “Completing this uplisting allows us greater visibility within the investment community, and enables us to target larger investors and bankers whose requirements include being current in our reporting. The OTCQB Market is one step away from the highest tier on the OTC Markets, and reaching it is yet another milestone in our efforts to unlock shareholder value through proper reporting and financial transparency. We believe it will help us to broaden our shareholder base, and propel our Company forward as a regulated and viable investment.”
The OTCQB Venture Market is designed for early-stage and developing companies located both in the United States and abroad. To be eligible for listing on the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process. Companies must also meet a minimum bid price test, which the Company meets. The OTCQB is recognized by the U.S. Securities and Exchange Commission as an established public market and provides current public information to investors that need to analyze, value and trade securities.
In recent months, the Company has demonstrated tremendous progress in both its clinical development program as well as its direct-to-consumer nutraceutical product portfolio. It is in the process of completing a pharmacokinetic (PK) study on its lead drug candidate Escozine® per an instructional response from the US Food and Drug Administration (FDA) as it relates to the Company’s pre-Investigational New Drug (Pre-IND) application for Escozine®. Additionally, it has ramped up its sales and marketing initiatives on its consumer products including the attendance and sponsorship of the Tony Hawk Vert Alert event, where it showcased its revolutionary line of pain relief products and introduced its Immunapen™ line of products.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc. (QNTA.NaE), a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary Aelia, Medolife manufactures and distributes consumer wellness and nutraceutical products in high-impact consumer areas such as pain relief, beauty, and general wellness. Aelia products are designed using Dr. Mikaelian’s polarization technology which applies advances in quantum biology to increase the potency of active ingredients. Currently, Aelia supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
ir@medoliferx.com
Image: https://www.globenewswire.com/newsroom/ti?nf=ODM4NTYwMCM0NTMwMDQ1IzUwMDA3MjQxNA==
Image: https://ml.globenewswire.com/media/ZmIzZTU0NjktNGE4Ny00ZTBiLWEwZmUtMzA0MTEyZTRjM2FmLTUwMDA3MjQxNA==/tiny/Quanta-Inc-.png
Image: Primary Logo
Source: Quanta, Inc. (QNTA.NaE)
GoodB(u)y PinkieLand and Welcome OTCQuarterBound...
https://www.otcmarkets.com/stock/QNTA/profile
You Mouse is Faster by 30secs here'''
https://stocktwits.com/symbol/QNTA
https://www.otcmarkets.com/stock/QNTA/profile
Do it Fast SCAM Sell it Mkt.eom
^$
My PennyStock a Year ago OCGN now Trading in the High 15.^$ eom
Global COVID-19 death toll tops 5M
https://www.msn.com/en-us/news/us/more-than-5-000-000-dead/ar-AAQcBPB?ocid=msedgdhp&pc=W069
COVID-19 Positive...
Biden’s Spokeswoman Diagnosed With Covid After Skipping Trip
https://www.msn.com/en-us/news/politics/biden-s-spokeswoman-diagnosed-with-covid-after-skipping-trip/ar-AAQa3Gd?ocid=msedgntp
The Whole World Needs Escozine ®
https://finance.yahoo.com/quote/QNTA?p=QNTA&.tsrc=fin-srch
NO DILUTION GOING ON!!!It's a RETAIL CLOSING OUT Account.My BID was FILLLED
@ 0.021 Moooolllaahhh.
REDICULOUSLY FREAKKIN CHEAP.Loved it.
S.C.A.M?ha ha ha Id10t!!!
NIH DD: Smp76, a Scorpine-Like Peptide Isolated from the Venom of the Scorpion Scorpio maurus palmatus, with a Potent Antiviral Activity Against Hepatitis C Virus and Dengue Virus
https://pubmed.ncbi.nlm.nih.gov/32435168/
Abstract
Growing global viral infections have been a serious public health problem in recent years.
This current situation emphasizes the importance of developing more therapeutic antiviral compounds.
Hepatitis C virus (HCV) and dengue virus (DENV) belong to the Flaviviridae family and are an increasing global health threat.
Our previous study reported that the crude venom of Scorpio maurus palmatus possessed anti-HCV and anti-DENV activities in vitro.
We report here the characterization of a natural antiviral peptide (scorpion-like peptide Smp76) that prevents HCV and DENV infection.
Smp76 was purified from S. m. palmatus venom and contains 76 amino acids with six residues of cysteine.
Smp76 antiviral activity was evaluated using a cell culture technique utilizing Huh7it-1, Vero/SLAM, HCV (JFH1, genotype 2a) and DENV (Trinidad 1751, type 2).
A potential antiviral activity of Smp76 was detected in culture cells with an approximate IC50 of 0.01 µg/ml. Moreover, Smp76 prevents HCV infection and suppresses secondary infection, by inactivating extra-cellular infectious particles without affecting viral replication.
Interestingly, Smp76 is neither toxic nor hemolytic in vitro at a concentration 1000-fold higher than that required for antiviral activity. Conclusively, this report highlights novel anti-HCV and anti-DENV activities of Smp76, which may lay the foundation for developing a new therapeutic intervention against these flaviviruses.
Humans around The World are getting Sicker and Current Advance Science is Not Fast enough to Combat the Alarming Epidemic..Is It?(Me thinks it is being Muffled by the Big Pharmas for the Sake of Mother Dollar).
Medolife Rx will soon Address the Blue Scorpion Venom Supply and Demand Issues.
NIH DD: The Scorpion Venom Peptide Smp76 Inhibits Viral Infection by Regulating Type-I Interferon Response
https://pubmed.ncbi.nlm.nih.gov/30569290/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335219/
Abstract
Dengue virus (DENV) and Zika virus (ZIKV) have spread throughout many countries in the developing world and infect millions of people every year, causing severe harm to human health and the economy.
Unfortunately, there are few effective vaccines and therapies available against these viruses.
Therefore, the discovery of new antiviral agents is critical. Herein, a scorpion venom peptide (Smp76) characterized from Scorpio maurus palmatus was successfully expressed and purified in Escherichia coli BL21(DE3).
The recombinant Smp76 (rSmp76) was found to effectively inhibit DENV and ZIKV infections in a dose-dependent manner in both cultured cell lines and primary mouse macrophages.
Interestingly, rSmp76 did not inactivate the viral particles directly but suppressed the established viral infection, similar to the effect of interferon (IFN)-ß.
Mechanistically, rSmp76 was revealed to upregulate the expression of IFN-ß by activating interferon regulatory transcription factor 3 (IRF3) phosphorylation, enhancing the type-I IFN response and inhibiting viral infection.
This mechanism is significantly different from traditional virucidal antimicrobial peptides (AMPs).
Overall, the scorpion venom peptide Smp76 is a potential new antiviral agent with a unique mechanism involving type-I IFN responses, demonstrating that natural AMPs can enhance immunity by functioning as immunomodulators.
TradeCast:A Blue Sky is Looming Above the Current Dark Cumulus Clouds @ Medolife Rx 2 Blue Scorpion Farms (Largest in The World) in DR.
Current Events:Respiratory Virus Spikes In California As Twindemic Threat Looms
https://www.msn.com/en-us/health/medical/respiratory-virus-spikes-in-california-as-twindemic-threat-looms/ar-AAQ92Gj?ocid=msedgntp
Many presume it’s the flu that laid them low, but influenza isn’t really spreading in California, according to the state health department’s weekly tabulations of confirmed cases.
The culprit is most likely Respiratory Syncytial Virus, a seasonal bug that doesn’t usually hit until winter but exploded across the state in the heat of the summer.
Infants and seniors are most susceptible to severe bouts of RSV leading to hospitalization.